The purpose of this resource is to provide tissue, cells and pathology services to all 4 research projects and to career or research development awardees covered by this application. To achieve these goals, we have integrated pathology resources from the Dan L Duncan Cancer Center at Baylor College of Medicine (BCM) and its affiliated institutions, with those from The Methodist Hospital. This integration both ensures adequate sample numbers and the timely delivery of tissue/cell samples for the needs of project investigators. The core acquires tissues for banking from lymphoma and CLL patients at affiliated hospitals in the Texas Medical Center, exploiting tissue collection and distribution systems that are already in place and that meet TCGA guidelines. Over the past 4 years, the core has successfully provided fresh cells and tissue, FFPE tissue, DNA, and RNA, tissue microarrays, marrow and serum to SPORE and external investigators. The core also provides pathology services, including routine tissue preparation, immunohistochemical staining, laser capture microdissection, preparation of tissue microarrays, flow cytometry, detection of minimal residual disease and in situ hybridization for viral RNAs. In addition, the core contains a cancer genetics laboratory for specialized molecular studies, including FISH and sequencing. These resources are provided by expert pathologists, histotechnologists and molecular biologists with substantial experience in providing core services to SPORE investigators. Finally, the bioinformatics group has expertise in working with the BCM Breast SPOREs to utilize CaTissue resources and has developed both bioinformatics and tissue-banking software needs for the lymphoma SPORE.

Public Health Relevance

The Biospecimen and Pathology Core coljects biospecimens needed by all investigators in this SPORE as well as for other investigators performing lymphoma research for their translational research projects. It provides pathology services to investigators and supports the clinical trials

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA126752-07
Application #
8547760
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
7
Fiscal Year
2013
Total Cost
$284,721
Indirect Cost
$66,822
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Rouce, Rayne H; Heslop, Helen E (2016) Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov 6:579-80
Yang, Liubin; Rodriguez, Benjamin; Mayle, Allison et al. (2016) DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell 29:922-34
Bollard, Catherine M; Heslop, Helen E (2016) T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 127:3331-40
Rouce, Rayne H; Sharma, Sandhya; Huynh, Mai et al. (2016) Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol :
Ramos, Carlos A; Heslop, Helen E; Brenner, Malcolm K (2016) CAR-T Cell Therapy for Lymphoma. Annu Rev Med 67:165-83
Ramos, Carlos A; Savoldo, Barbara; Torrano, Vicky et al. (2016) Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest 126:2588-96
Rau, Rachel E; Rodriguez, Benjamin A; Luo, Min et al. (2016) DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128:971-81
Zhou, Xiaoou; Naik, Swati; Dakhova, Olga et al. (2016) Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther 24:823-31
Eckstein, Olive S; Wang, Linghua; Punia, Jyotinder N et al. (2016) Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol 44:740-4
Naik, Swati; Nicholas, Sarah K; Martinez, Caridad A et al. (2016) Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 137:1498-1505.e1

Showing the most recent 10 out of 218 publications